Pharming Group N.V. (PHAR)

NASDAQ: PHAR · IEX Real-Time Price · USD
+0.72 (7.02%)
At close: Aug 15, 2022 4:00 PM
+0.02 (0.18%)
After-hours: Aug 15, 2022 4:25 PM EDT
Market Cap 711.68M
Revenue (ttm) 213.05M
Net Income (ttm) 21.94M
Shares Out 64.87M
EPS (ttm) 0.31
PE Ratio 35.39
Forward PE 454.55
Dividend n/a
Ex-Dividend Date n/a
Volume 2,386
Open 10.65
Previous Close 10.25
Day's Range 10.60 - 10.97
52-Week Range 6.10 - 11.05
Beta 1.39
Analysts Buy
Price Target 86.80 (+691.2%)
Earnings Date Aug 4, 2022

About PHAR

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (... [Read more...]

Industry Biotechnology
Founded 1988
CEO Sijmen de Vries
Employees 277
Stock Exchange NASDAQ
Ticker Symbol PHAR
Full Company Profile

Financial Performance

In 2021, Pharming Group's revenue was 198.87 million, a decrease of -6.27% compared to the previous year's 212.17 million. Earnings were 16.00 million, a decrease of -57.62%.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for PHAR stock is "Buy." The 12-month stock price forecast is 86.8, which is an increase of 691.25% from the latest price.

Price Target
(691.25% upside)
Analyst Consensus: Buy
Stock Forecasts


Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Implemented by the Centers for Disease Control and Prevention, the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts LEIDEN, Netherlands , Aug. 2, 2022 ...

Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS

EMA  accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2...

Pharming receives agreement of Paediatric Investigation Plan and Promising Innovative Medicine designation for leniol...

An agreed Paediatric Investigation Plan (PIP) is the regulatory pathway to market authorization for leniolisib as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children A ...

Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Ann...

LEIDEN, Netherlands , April 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces new data from the pivotal Phase II/III trial of l...

Why Are Pharming Shares Trading Higher Today?

Pharming Group NV PHAR has announced results from the Phase 2/3study of leniolisib for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), an ultra-rare primary immunodeficiency disease. ...